MACE an unreliable endpoint in cardiovascular studies

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1626, 2008-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?

Current Pharmaceutical Design, Vol. 13, Iss. 17, 2007-06 ,pp. : 1741-1750

Bentham Science Publishers

Access to resources Recommend Favorite

Candesartan cilexetil can make a difference to MACE rates

Inpharma, Vol. 1, Iss. 1647, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Cardiovascular

Current Bioactive Compounds, Vol. 2, Iss. 3, 2006-09 ,pp. : 367-372

Bentham Science Publishers

Access to resources Recommend Favorite

Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies

By Chan W.Y. Levi R. Wo N.C. Koyama M. Stoev S. Cheng L.L. Manning M.

European Journal of Pharmacology, Vol. 419, Iss. 1, 2001-05 ,pp. : 65-72

Elsevier

Access to resources Recommend Favorite

Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 1, 2013-03 ,pp. : 4-12

Bentham Science Publishers

Access to resources Recommend Favorite